Two doses of mRNA-1345 respiratory syncytial virus (RSV) vaccine 50 µg administered 56 days apart do not yield any safety concerns and are well-tolerated among solid organ transplant recipients (SOTRs), according to a study presented at IDWeek 2025.
The novel mRNA-based influenza vaccine mRNA-1010 has demonstrated superior efficacy over its standard-dose (SD) comparator in preventing RT-PCR–confirmed protocol-defined influenza disease in adults aged 50 years and above, reports a study presented at IDWeek 2025.
